3647 results for «604»
3647 results
Optimising TAVI care pathways
21 May 2026 – From EuroPCR 2026
This session examines innovations in TAVI care pathways aimed at improving patient outcomes and healthcare efficiency. Topics include large-scale transatlantic data on day-case TAVI, standardized ECG conduction algorithms reducing hospital stay, nurse-led structured pathways, feasibility of very early discharge, and urgent outpatient TAVI for severe aortic...
Fighting intracardiac masses
21 May 2026 – From EuroPCR 2026
This session focuses on the percutaneous management of intracardiac masses, presenting innovative approaches such as angiovac-assisted vegetation removal, management of mechanical mitral valve complications, and treatment options for right ventricular tumors. It also evaluates the emerging role of percutaneous therapies in infective endocarditis involving TAVI valves...
Imaging-guided calcified lesion PCI
21 May 2026 – From EuroPCR 2026
This session presents state-of-the-art imaging-guided interventions for calcified coronary lesions, showcasing modalities such as lithotripsy, rotational atherectomy, and complex calcium modification techniques. It includes case studies highlighting zero-contrast PCI and stenting in challenging anatomies, including left main bifurcation lesions in elderly patients with complex clinical backgrounds.
CTO PCI: understand it, love it
21 May 2026 – From EuroPCR 2026
This educational session provides a comprehensive overview of chronic total occlusion (CTO) PCI, elucidating key procedural steps, essential materials, and potential complications. It highlights the significant role of nurses and allied health professionals in supporting the procedure and enhancing patient experience throughout the pre-, intra-, and...
Which AF patients may benefit from LAA closure?
02 Jul 2026
Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author
Future directions of drug-coated balloon angioplasty
06 Feb 2025
Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Author

Author